Pharmaceutical company VIVUS (NAS: VVUS) has been officially notified that the European Medicines Agency (EMA) will not approve its weight-loss drug Qsymia. In a previous video, we covered what this news could mean for VIVUS going forward -- but what impact does it have on its chief rival, Arena Pharmaceuticals (NAS: ARNA) ? Does this mean that Arena's drug Belviq will dominate the market if it gains EMA approval next year? Instead, could this decision mean that all weight-loss drugs -- including Belviq -- will be intensely scrutinized before they can hit the European market?
In the following video, Health Care Analysts Max Macaluso and David Williamson discuss how this news could affect Arena's future.
When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
The article Is VIVUS' Loss Arena's Gain? originally appeared on Fool.com.
Max Macaluso, Ph.D., David Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.